The objective was to determine the effects of injectable trace minerals (ITM, containing Se, Cu, Zn & Mn) administered at the time of primary intranasal (IN) modified-live virus (MLV) vaccination of young dairy calves on the serum neutralizing antibody (SNA) titers to Bovine herpes virus 1 (BHV1), Bovine respiratory syncytial virus (BRSV), and Bovine Parainfluenza type 3 virus (BPIV); cytokine expression in peripheral white blood cells, and BHV1-specific IgA titers in nasal secretions following the vaccination. A total of 60 calves (1 month old) were administered an IN MLV vaccine containing BHV1, BRSV, BPIV (Inforce 3) and randomly assigned to one of two experimental groups: ITM (n = 30; Multimin90, containing Se, Cu, Zn, and Mn) or SAL (n = 30; sterile saline). There was a consistent decay in virus-specific SNA titers in both groups. Calves with ITM had significantly greater BRSV-SNA titers on day 14 (p = 0.045), and day 28 (p = 0.028) than SAL calves. There was a significant increase in BHV1-specific IgA in nasal secretion in both groups, without significant difference. In conclusion, IN vaccination of dairy calves with high levels of maternally derived SNA did not produce a significant increase in SNA titers to the vaccine viruses but did stimulate a significant BHV1-IgA response in nasal secretions. Supplementation with ITM was associated with a delayed decrease of BRSV-SNA titers on days 14 and 28 after primary vaccination. Administration of ITM was also associated with lower clinical scores and respiratory disease morbidity and mortality. Treatment with ITM did not affect SNA titers to BHV1 and BPI3V or the BHV1-specific IgA level in nasal secretions.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11259-024-10630-7DOI Listing

Publication Analysis

Top Keywords

sna titers
16
dairy calves
12
bhv1-specific iga
12
nasal secretions
12
effects injectable
8
injectable trace
8
trace minerals
8
primary intranasal
8
intranasal modified-live
8
modified-live virus
8

Similar Publications

The objective was to determine the effects of injectable trace minerals (ITM, containing Se, Cu, Zn & Mn) administered at the time of primary intranasal (IN) modified-live virus (MLV) vaccination of young dairy calves on the serum neutralizing antibody (SNA) titers to Bovine herpes virus 1 (BHV1), Bovine respiratory syncytial virus (BRSV), and Bovine Parainfluenza type 3 virus (BPIV); cytokine expression in peripheral white blood cells, and BHV1-specific IgA titers in nasal secretions following the vaccination. A total of 60 calves (1 month old) were administered an IN MLV vaccine containing BHV1, BRSV, BPIV (Inforce 3) and randomly assigned to one of two experimental groups: ITM (n = 30; Multimin90, containing Se, Cu, Zn, and Mn) or SAL (n = 30; sterile saline). There was a consistent decay in virus-specific SNA titers in both groups.

View Article and Find Full Text PDF
Article Synopsis
  • Clesrovimab is a new monoclonal antibody designed to prevent respiratory syncytial virus (RSV) disease in infants, tested in a study with 183 healthy infants aged 2 weeks to 8 months.
  • The study found that Clesrovimab was well tolerated, with the most common side effect being irritability, and it demonstrated a long half-life of 44.9 days, along with improved serum neutralizing antibodies over time.
  • Infants who received Clesrovimab had lower rates of RSV-related illnesses compared to those given a placebo, indicating its potential effectiveness for further development in clinical trials.
View Article and Find Full Text PDF

Background: Clesrovimab is a human half-life extended mAb in phase 3 evaluation for the prevention of RSV disease in infants. ADA were observed at late time points in a phase 1b/2a study where clesrovimab was well tolerated with an extended half-life of ∼45 days.

Methods: Serum samples at days 150, 365 and 545 post-dose were assayed for ADA titers.

View Article and Find Full Text PDF

Background: The global prevalence of Dengue virus (DENV) infection poses a significant health risk, urging the need for effective vaccinations. Peptide vaccines, known for their capacity to induce comprehensive immunity against multiple virus serotypes, offer promise due to their stability, safety, and design flexibility. Spherical nucleic acid (SNA), particularly those with gold nanoparticle cores, present an attractive avenue for enhancing peptide vaccine efficacy due to their modularity and immunomodulatory properties.

View Article and Find Full Text PDF

Oligonucleotides are powerful molecules for programming function and assembly. When arrayed on nanoparticle scaffolds in high density, the resulting molecules, spherical nucleic acids (SNAs), become imbued with unique properties. We used the copper-catalyzed azide-alkyne cycloaddition to graft oligonucleotides on Qβ virus-like particles to see if such structures also gain SNA-like behavior.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!